1
Clinical Trials associated with Mutant p53 peptide pulsed dendritic cell vaccine(University of Pittsburgh)Adjuvant p53 Peptide Loaded DC-Based Therapy for Subjects With Squamous Cell Cancer of the Head and Neck (A Phase I Safety and Immunogenicity Trial)
RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects of vaccine therapy in treating patients with head and neck cancer.
100 Clinical Results associated with Mutant p53 peptide pulsed dendritic cell vaccine(University of Pittsburgh)
100 Translational Medicine associated with Mutant p53 peptide pulsed dendritic cell vaccine(University of Pittsburgh)
100 Patents (Medical) associated with Mutant p53 peptide pulsed dendritic cell vaccine(University of Pittsburgh)
100 Deals associated with Mutant p53 peptide pulsed dendritic cell vaccine(University of Pittsburgh)